NCT06105749 - Biennial CEM in Women With a Personal History of Breast Cancer | Biotech Hunter

Enrollment

1,500

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

December 31, 2029

Study Completion Date

April 30, 2031

Conditions

Breast CancerBreast NeoplasmsBreast Cancer FemaleNeoplasms

Interventions

DEVICE

contrast-enhanced mammography

Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.

Trial Locations (6)

15102

RECRUITING

UPMC Magee-Womens Imaging - Bethel Park, Bethel Park

15146

RECRUITING

Magee Womancare Monroeville, Monroeville

15213

RECRUITING

Magee-Womens Hospital, Pittsburgh

15232

RECRUITING

Hillman Cancer Center at Shadyside, Pittsburgh

15236

RECRUITING

UPMC West Mifflin Outpatient Center, West Mifflin

16066

RECRUITING

UPMC Magee at the Lemieux Sports Complex, Cranberry Township